Should You Dump AstraZeneca plc In Favour Of GlaxoSmithKline plc?

AstraZeneca plc (LON: AZN) currently trades at a premium to GlaxoSmithKline plc (LON: GSK); does it deserve it?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskGlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and AstraZeneca (LSE: AZN) (NYSE: AZN.US) have both had very different fortunes since the beginning of the year. On one hand, AstraZeneca’s shares have surged higher around 15%, beating the FTSE 100 approximately 14%. On the other, Glaxo has floundered, rising a lacklustre 5%.

But after this impressive performance, are AstraZeneca’s shares overvalued and should you dump your holding in favour of larger peer Glaxo? 

A quick look at valuation

The quickest way to gauge whether or not AstraZeneca is overvalued is to take a look at the company’s valuation, although this is by no means a definitive analysis.

Should you invest £1,000 in Burberry Group Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Burberry Group Plc made the list?

See the 6 stocks

At present, Glaxo is currently trading at a forward P/E of 15 for 2014, in comparison, AstraZeneca is trading at a forward P/E of 15.7, which does not seem overly expensive at first glance.

However, AstraZeneca’s earnings per share are expected to fall around 14% during 2014, while Glaxo’s EPS are forecast to remain unchanged, implying that AstraZeneca should actually be trading at a discount to Glaxo. Additionally, Glaxo’s dividend yield now stands at 4.7%, AstraZeneca’s yield currently sits at 4.1%, rising to 4.2% next year. 

The fundamentals support Glaxo

AstraZeneca has been grappling with sliding sales for some time now, thanks to the loss of exclusive manufacturing rights for a number of its treatments. Actually, according to the company’s own management, sales are going to continue to decline for some years to come. Specifically, AstraZeneca’s CEO Pascal Soriot does not expect AstraZeneca’s revenue to return to 2013 levels until 2017. This implies that the market is placing too much of a premium on the company.

Further, AstraZeneca only brought 11 treatments to Phase III trials during 2013 but none of these new products will file for regulatory approval before 2016. In comparison, Glaxo had five new drugs approved for sale during 2013 and a further 40 are in late stage development. With this being the case it would appear silly to suggest that AstraZeneca should trade at the same valuation as Glaxo, which it currently does. 

Summary

All in all, looking at the evidence above, I feel that perhaps investors should dump AstraZeneca in favour of Glaxo.

With multiple new treatments coming to market over the next few years, sales continuing to expand and a dividend yield of 4.7%, Glaxo would appear to be a better choice than AstraZeneca, which continues to report sliding sales and boasts an unimpressive treatment pipeline. 

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Rupert does not own any share mentioned within this article. The Motley Fool has recommended shares in GlaxoSmithKline. 

Like buying £1 for 51p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

Smart young brown businesswoman working from home on a laptop
Investing Articles

Down 15% in a week! Are these 5 FTSE 100 fallers screaming buys as markets plunge?

Five of Harvey Jones's favourite FTSE 100 stocks all have the same thing in common – they've fallen around 15%…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

2 stocks that have been crushed and now offer a ton of value

Edward Sheldon has been scanning the market for stocks that offer value after the sell-off. Here are two shares he…

Read more »

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

£10,000 invested in Aston Martin shares at Christmas is now worth…

Aston Martin shares have fallen from above £10 in early 2020 to pennies today. Is this the perfect time for…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Investing Articles

Up 5% in the last crazy week! Are these 2 income stocks the ultimate FTSE defensive plays?

Harvey Jones picks out two FTSE 100 dividend income stocks that have actually climbed while stock markets are heading in…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

2 beaten-down UK shares that now look really cheap

Looking for cheap shares to consider for the long term? These two British stocks offer a lot of value right…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

As stocks tank, is this a rare chance for ISA investors to get rich?

Shares have collapsed globally and valuations are becoming, on paper at least, a lot more attractive. Dr James Fox explores…

Read more »

Investing Articles

2 strong FTSE 100 dividend shares to consider as recessionary risks increase

Looking for secure passive income stocks to consider buying as thumping trade tariffs loom? Here are two FTSE 100 dividend…

Read more »

Investing Articles

Can Greggs shares offer shelter from Trump’s tariff chaos?

Greggs' shares have plummeted in recent months. But with very little exposure to the US or tariffs, could the stock…

Read more »